Hepatitis C cirrhosis: New perspectives for diagnosis and treatment

doi:10.4254/wjh.v7.i14.1843

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 14

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7685)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-7) series.

Item

Count

PDF

464

WORD

270

HTML

4164

Figures (1-1)

162

Tables (1-7)

162

Sum=5222

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1069

Download

1394

Sum=2463

Jul 18, 2015 (publication date) through Apr 27, 2024

Times Cited of This Article

Times Cited (38)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Hepatol. Jul 18, 2015; 7(14): 1843-1855
Published online Jul 18, 2015. doi: 10.4254/wjh.v7.i14.1843

Table 7 Summary of sofosbuvir and ledipasvir trials and enrollment of cirrhotic patients

Trial	Regimen	Patient population (% with cirrhosis)	Duration (wk)	SVR12
ION-1[45]	SOF + LDP	212 naïve (16%)	12	99%
	SOF + LDP + RBV	211 naïve (15%)	12	97%
	SOF + LDP	214 naïve (15%)	24	98%
	SOF + LDP + RBV	215 naïve (17%)	24	99%
ION-2[46]	SOF + LDP	109 treatment experienced (20%)	12	94%
	SOF + LDP + RBV	111 treatment experienced (20%)	12	96%
	SOF + LDP	109 treatment experienced (20%)	24	99%
	SOF + LDP + RBV	111 treatment experienced (20%)	24	99%
ION-3[47]	SOF + LDP	215 naïve (0%)	8	94%
	SOF + LDP + RBV	216 naïve (0%)	8	93%
	SOF + LDP	216 naïve (0%)	12	95%

SOF: Sofosbuvir; LDP: Ledipasvir; RBV: Ribavirin; SVR12: Sustained virologic response at 12 wk.

Citation: Khullar V, Firpi RJ. Hepatitis C cirrhosis: New perspectives for diagnosis and treatment. World J Hepatol 2015; 7(14): 1843-1855
URL: https://www.wjgnet.com/1948-5182/full/v7/i14/1843.htm
DOI: https://dx.doi.org/10.4254/wjh.v7.i14.1843